Table 3.

CaBP modulation through overexpression or knockout under in vivo and in vitro conditions.

CaBP	Conditions	Gene Manipulation (↑, Overexpression; ↓, Knockout)	Neuronal Population	Insult	Supportive of Neuroprotective Role?	Ref.
PV	In vitro	↑	Cortical neurons	NMDA exposure	No	[70]
	In vivo	↑	Spinal motor neurons	KA exposure	Yes	[71]
	In vitro	↓	Temporal lobe	Epilepsy model	No	[72]
	In vitro	↑	Neuroblastoma-retina hybrid cells	Glutamate exposure	No	[73]
	In vitro	↑	P19 cell line	NMDA exposure	No	[74]
CB	In vivo	↓	Hippocampus	Age-mediated decline	Yes	[75]
	In vivo	↓	Midbrain dopaminergic neurons	MPTP injection	No	[76]
	In vivo	↓	Subiculum	Alzheimer genetic model	Yes	[77]
	In vivo	↓	Hippocampal CA1 pyramidal neurons	Ischemia model	No	[51]
	In vitro	↑	SOD-1 mutant motor neurons	Glutamate exposure	Yes	[78]
	In vitro	↑	Hippocampal neurons	Glutamate exposure	Yes	[79]
	In vivo	↑	Hippocampus	KA and 3-AP exposure	Yes	[80]
	In vitro	↓	Temporal lobe	Epilepsy model	No	[72]
	In vitro	↑	Neuroblastoma-retina hybrid cells	Glutamate exposure	Yes	[73]
	In vitro	↑	P19 cell line	NMDA exposure	Yes	[74]
CR	In vitro	↑	PC12 cell line	Ionophore exposure and serum/growth factor withdrawal	No	[81]
	In vivo	↓	Temporal lobe	Epilepsy model	No	[72]
	In vitro	↑	Neuroblastoma-retina hybrid cells	Glutamate exposure	Yes	[73]
	In vitro	↑	P19 cell line	NMDA exposure	Yes	[74]

3-AP, 3-acetylpyridine; CB, calbindin, CR, calretinin; KA, kainic acid; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NMDA, N-Methyl-D-aspartate; SOD-1, superoxide dismutase-1; PV, parvalbumin.